Alembic Pharma (Mid Cap) Share Target 2026, 2027 To 2035
|
Alembic Pharmaceuticals Limited |
|||
|
Price: ₹737.75 (-0.75%) | ||
| 52 Week Low: ₹635.80 52 Week High: ₹1,107.90 |
|||
| Market Capital: 14,762.87 Crore (Mid-cap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Alembic Pharma Share Price Target For 2026
- 1.1.1: Alembic Pharma Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Alembic Pharma Share Price Target For 2027
- 1.2.1: Alembic Pharma Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Alembic Pharma Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Alembic Pharma Brief Company Overview
- 4: Alembic Pharma Financial Performance
- 4.0.1: Is Alembic Pharma A Good Buy For Long Term?
Alembic Pharma, a Mid Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 20.7% returns in 3-year showing 3.3% quarterly revenue growth with 10.2% profit margin.
To predict the Alembic Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Alembic Pharma Share Price Target For 2026
The line chart displays the monthly closing prices of Alembic Pharma with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Alembic Pharma shares in 2026, see the table below.
Alembic Pharma Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 765.35 (+3.74%) | Volatility: BB Upper |
| 2026 Target 2 | 747.17 (+1.27%) | Trend: SMA50 |
| 2026 Target 1 | 738.40 (+0.08%) | Trend: EMA9 |
| Current Price | 737.75 | Alembic Pharma's share price as of 15 Jun 2026 |
| Stop Loss 1 | 716.61 (-2.87%) | Volatility: BB Lower |
| Stop Loss 2 | 676.18 (-8.35%) | Volatility: ATR S1 |
| Stop Loss 3 | 642.41 (-12.93%) | 98.60% Weekly Fib Retrace |
Short-Term Technical Outlook
Current Technical Position: Alembic Pharma is showing mixed momentum signals near key moving averages.
Key Technical Level: The 50-day moving average at ₹747.17 serves as the nearest technical reference point.
Historical Returns: 3-month: +9.25% | 6-month: -14.68% | 1-year: -25.6%
Alembic Pharma Share Price Target For 2027
The line chart displays the monthly closing prices of Alembic Pharma with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Alembic Pharma shares in 2027, see the table below.
Alembic Pharma Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 765.35 (+3.74%) | Volatility: BB Upper |
| 2027 Target 2 | 747.17 (+1.27%) | Trend: SMA50 |
| 2027 Target 1 | 738.40 (+0.08%) | Trend: EMA9 |
| Current Price | 737.75 | Alembic Pharma's share price as of 15 Jun 2026 |
| Stop Loss 1 | 716.61 (-2.87%) | Volatility: BB Lower |
| Stop Loss 2 | 676.18 (-8.35%) | Volatility: ATR S1 |
| Stop Loss 3 | 642.41 (-12.93%) | 98.60% Weekly Fib Retrace |
Long-Term Technical Outlook
52-Week Range Analysis: Alembic Pharma is currently trading near its 52-week low of ₹635.8, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -25.6% | 3-year: +20.7% | 5-year: -23.84%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Alembic Pharma Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹737.75 | ||
| 2026 | ₹899.99 | +21.991189427313% | ₹913.49 |
| 2027 | ₹1,005.24 | +11.69457438416% | ₹1,020.32 |
| 2028 | ₹1,084.05 | +7.8399188253551% | ₹1,100.31 |
| 2029 | ₹1,149.00 | +5.9914210599142% | ₹1,166.24 |
| 2030 | ₹1,285.26 | +11.859007832898% | ₹1,304.54 |
| 2031 | ₹1,380.52 | +7.4117299223503% | ₹1,401.23 |
| 2032 | ₹1,496.94 | +8.4330542114566% | ₹1,519.39 |
| 2033 | ₹1,454.54 | -2.8324448541692% | ₹1,476.36 |
| 2034 | ₹1,564.57 | +7.5645908672158% | ₹1,588.04 |
| 2035 | ₹1,733.11 | +10.772288871703% | ₹1,759.11 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Alembic Pharma Brief Company Overview
Alembic Pharmaceuticals Limited: A Trusted Name in Pharmaceuticals Established in 1907, Alembic Pharmaceuticals Limited is a leading Indian pharmaceutical company with a global footprint. The company offers a diverse range of branded specialty medicines in areas such as...
cardiology, gynecology, and ophthalmology. It also manufactures generic formulations in various categories, including oral solids, injectables, and ophthalmic products. Reputation: Alembic Pharmaceuticals Limited enjoys a strong reputation for quality and innovation within the industry. Commitment: The company is committed to providing affordable and accessible healthcare solutions to patients worldwide.Alembic Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 20,176.07 Crore | Market valuation of Alembic Pharma's shares. |
| Revenue (TTM) | 6,357.25 Crore | Total revenue generated by Alembic Pharma over the past twelve months. |
| Net Income (TTM) | +646.78 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 10.24% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 10.17% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+3.3% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+12.3% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
21.81 | Company's total debt divided by total shareholder equity. |
| Total Debt | 1,066.34 Crore | Sum of Alembic Pharma's current & long-term financial obligations. |
| Total Cash | 128.95 Crore | Total amount of liquid funds available to Alembic Pharma. |
| Beta | 0.69 | Beta is less than 1 indicating that the Alembic Pharma's price is less volatile than the market. |
Is Alembic Pharma A Good Buy For Long Term?
Alembic Pharma (market cap: ₹20,176.07 Crore) shows mixed signals. While its strong revenue (₹6,357.25 Crore) and impressive 12-month return (46.11%) are positive, a debt of ₹1,066.34 Crore (Q2 2024-25) needs consideration. The 10.17% profit margin and recent 3-month decline (-11.68%) temper enthusiasm. Long-term prospects depend on debt management and sustained revenue growth. Therefore, Alembic Pharma is an average buy for long-term investors, warranting further in-depth analysis before a final decision.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
